Production (Stage)
Autolus Therapeutics plc
AUTL
$1.54
$0.010.65%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -10.99% | -- | -- | -- | 681.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -10.99% | -- | -- | -- | 681.04% |
| Cost of Revenue | 45.69% | 17.87% | -20.13% | 10.17% | 11.99% |
| Gross Profit | -73.48% | -17.85% | -8.85% | -10.17% | 21.14% |
| SG&A Expenses | 62.48% | 77.77% | 157.56% | 96.93% | 95.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.94% | 42.47% | 57.59% | 31.93% | 33.20% |
| Operating Income | -68.32% | -42.41% | -59.10% | -31.93% | -9.54% |
| Income Before Tax | -28.92% | 66.13% | -78.92% | -27.92% | -32.32% |
| Income Tax Expenses | 27,912.50% | 6,191.67% | 204.76% | 27.50% | 42.86% |
| Earnings from Continuing Operations | -33.16% | 64.23% | -79.05% | -27.92% | -32.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.16% | 64.23% | -79.05% | -27.92% | -32.35% |
| EBIT | -68.32% | -42.41% | -59.10% | -31.93% | -9.54% |
| EBITDA | -70.39% | -43.29% | -59.72% | -32.16% | -10.36% |
| EPS Basic | -11.13% | 76.61% | -17.08% | 16.41% | -3.58% |
| Normalized Basic EPS | -7.62% | 77.95% | -17.69% | 16.94% | -14.35% |
| EPS Diluted | -11.13% | 76.61% | -17.08% | 16.41% | -3.58% |
| Normalized Diluted EPS | -7.62% | 77.95% | -17.69% | 16.94% | -14.35% |
| Average Basic Shares Outstanding | 19.78% | 52.91% | 52.94% | 53.01% | 27.81% |
| Average Diluted Shares Outstanding | 19.78% | 52.91% | 52.94% | 53.01% | 27.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |